Point-of-care screening for chromosomal anomalies in the first trimester of pregnancy

Clinical Chemistry

Volumn 48, Issue 3, 2002, Pages 403-404

  Spencer, Kevin ^a  

^a HAROLD WOOD HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; CHORIONIC GONADOTROPIN BETA SUBUNIT; DNA; PREGNANCY ASSOCIATED PLASMA PROTEIN A;

CHROMOSOME ABERRATION; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE MARKER; EDITORIAL; FETUS; FETUS ECHOGRAPHY; FIRST TRIMESTER PREGNANCY; GENETIC SCREENING; HUMAN; IMMUNOASSAY; PATIENT SATISFACTION; PRENATAL DIAGNOSIS; QUANTITATIVE DIAGNOSIS; RISK ASSESSMENT; TRISOMY 18; TRISOMY 21;

CHROMOSOME ABERRATIONS; CHROMOSOME DISORDERS; FEMALE; GENETIC SCREENING; HUMANS; POINT-OF-CARE SYSTEMS; PREGNANCY; PREGNANCY TRIMESTER, FIRST;

EID: 0036179264     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (19)

1. An association between low maternal serum α-fetoprotein and fetal chromosomal abnormalities
2. Impact of a regional screening programme using maternal serum AFP and hCG on the birth incidence of Down's syndrome in the west of Scotland
3. Second trimester prenatal screening for Down's syndrome using α-fetoprotein and free β hCG: A seven year review
4. Antenatal screening for Down's syndrome
5. Free β hCG as a first trimester of fetal trisomy
6. Ultrasound and biochemical assessment of first trimester pregnancy
7. UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10-14 weeks of gestation
8. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free β-human chorionic gonadotropin and pregnancy-associated plasma protein-A
9. Prenatal screening for neural tube defects and aneuploidy
10. Point-of-care time-resolved immunofluorometric assay for human pregnancy-associated plasma protein A suitable for use in first-trimester screening for Down syndrome
11. Near patient testing and Down's syndrome screening
12. Rare earth cryptates and homogeneous fluoroimmunoassay with human sera
13. A large-scale evaluation of amnio-PCR for the rapid prenatal diagnosis of fetal trisomy
14. One stop clinic for assessment of risk for fetal anomalies: A report of the first year of prospective screening for chromosomal anomalies in the first trimester
15. Integrated screening for Down's syndrome on the basis of tests performed during the first and second trimesters
16. Integrated test
17. Absence of nasal bone in fetuses with trisomy 21 at 11-14 weeks of gestation: An observational study
18. Increased fetal DNA concentrations in the plasma of pregnant women carrying fetuses with trisomy 21